Núcleo de Genética Humana e Molecular, Departamento de Ciências Biológicas, Universidade Federal do Espírito Santo (UFES), Vitória 29075-910, ES, Brazil.
Programa de Pós-Graduação em Biotecnologia, Universidade Federal do Espírito Santo, Vitória 29047-105, ES, Brazil.
Genes (Basel). 2023 Jun 28;14(7):1364. doi: 10.3390/genes14071364.
Breast cancer is the second most frequent cancer in the world. It is a heterogeneous disease and the leading cause of cancer mortality in women. Advances in molecular technologies allowed for the identification of new and more specifics biomarkers for breast cancer diagnosis, prognosis, and risk prediction, enabling personalized treatments, improving therapy, and preventing overtreatment, undertreatment, and incorrect treatment. Several breast cancer biomarkers have been identified and, along with traditional biomarkers, they can assist physicians throughout treatment plan and increase therapy success. Despite the need of more data to improve specificity and determine the real clinical utility of some biomarkers, others are already established and can be used as a guide to make treatment decisions. In this review, we summarize the available traditional, novel, and potential biomarkers while also including gene expression profiles, breast cancer single-cell and polyploid giant cancer cells. We hope to help physicians understand tumor specific characteristics and support decision-making in patient-personalized clinical management, consequently improving treatment outcome.
乳腺癌是全球第二大常见癌症。它是一种异质性疾病,也是女性癌症死亡的主要原因。分子技术的进步使得能够鉴定新的和更具体的乳腺癌诊断、预后和风险预测生物标志物,从而实现个体化治疗,改善治疗效果,并防止过度治疗、治疗不足和治疗不当。已经确定了几种乳腺癌生物标志物,它们与传统生物标志物一起,可以帮助医生制定治疗计划并提高治疗成功率。尽管需要更多的数据来提高特异性并确定一些生物标志物的真正临床实用性,但其他生物标志物已经确立,可以用作指导治疗决策的依据。在这篇综述中,我们总结了现有的传统、新型和潜在的生物标志物,同时还包括基因表达谱、乳腺癌单细胞和多倍体巨癌细胞。我们希望帮助医生了解肿瘤的特定特征,并支持在患者个体化临床管理中的决策制定,从而改善治疗结果。